BioVie’s Bezisterim Data on Parkinson’s Set for AD/PD 2026 Presentation
Event summary
- BioVie’s abstract on bezisterim (NE3107) for Parkinson’s Disease accepted at AD/PD 2026, to be presented March 17-21 in Copenhagen.
- SUNRISE-PD study enrolled 60 patients; topline results expected mid-2026.
- Bezisterim targets neuroinflammation and insulin resistance, with Phase 2 data showing motor control improvements in Parkinson’s.
- ADDRESS-LC trial for Long COVID enrolling ~200 patients, with topline data also due mid-2026.
The big picture
BioVie’s focus on neuroinflammation aligns with growing interest in modulating immune responses to treat neurodegenerative diseases. The dual-track approach—targeting both Parkinson’s and Long COVID with bezisterim—could expand its therapeutic pipeline, but success hinges on mid-2026 trial results. The company’s orphan drug designation for BIV201 in liver disease adds another layer of strategic diversification.
What we're watching
- Clinical Validation
- Whether bezisterim’s Phase 2 success in Parkinson’s translates to positive topline results from the SUNRISE-PD study mid-2026.
- Market Differentiation
- How BioVie positions bezisterim against competitors targeting neuroinflammation in Parkinson’s and Alzheimer’s.
- Regulatory Pathway
- The pace at which BioVie advances BIV201 through Phase 3 trials for liver disease, following FDA Fast Track designation.